Application of peripheral blood mononuclear cells circGSAP

A nuclear cell and peripheral blood technology, applied in the application field of peripheral blood mononuclear cell circGSAP

Pending Publication Date: 2021-06-15
SHANGHAI PULMONARY HOSPITAL
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Whether the serum circGSAP level can be used as a biomarker to evaluate the increased risk or increased survival rate of IPAH patients has not been reported in the prior art

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of peripheral blood mononuclear cells circGSAP
  • Application of peripheral blood mononuclear cells circGSAP
  • Application of peripheral blood mononuclear cells circGSAP

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0021] ① Research population

[0022] In May 2009, 6 newly admitted IPAH patients and 6 healthy controls were recruited as the discovery group. Sixty IPAH patients and 30 healthy controls were selected as the validation group. IPAH was diagnosed in both groups according to the then-current guidelines of the European Society of Cardiology and the European Respiratory Society. Specifically, the inclusion criteria for the two groups of patients were mPAP ≥ 25 mmHg, mPAWP ≤ 15 mmHg, and PVR > 3WU, and patients who excluded other causes of PAH. Patients with established etiologies associated with PAH, such as connective tissue disease and congenital heart disease, and patients with other pulmonary artery obstruction such as pulmonary hypertension due to left heart disease and chronic thromboembolic pulmonary hypertension were excluded. We also excluded patients with acute or chronic diseases that might affect plasma levels (ie, acute or chronic infections, chronic autoimmune dise...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of a preparation for detecting peripheral blood mononuclear cells circGSAP in preparation of a kit for predicting the survival rate of patients with idiopathic pulmonary hypertension. It is found for the first time that the expression levels of the peripheral blood mononuclear cells circGSAP of IPAH survivors and non-survivors are different. The peripheral blood mononuclear cells circGSAP can be used as an independent survival rate predictor, and provides a reference for evaluating the severity and clinical prognosis of the disease progress of the IPAH patient.

Description

technical field [0001] The present invention relates to the technical field of prognosis of idiopathic pulmonary hypertension, in particular to an application of peripheral blood mononuclear cells circGSAP. Background technique [0002] Idiopathic pulmonary arterial hypertension (IPAH) is a muscular pulmonary arteriolar disease characterized by progressive increases in pulmonary artery pressure and pulmonary vascular resistance (PVR) without apparent cause, eventually leading to death from right heart failure. The gold standard for the diagnosis of IPAH is based on multiple hemodynamic indicators of right heart catheterization (RHC), such as PVR, mean pulmonary artery pressure (mPAP), mean pulmonary artery wedge pressure (mPAWP), etc. In addition to their diagnostic value, some hemodynamic parameters can be used as biomarkers to assess the prognosis of IPAH patients. However, these parameters are obtained through invasive examinations, and better biomarkers are urgently nee...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6883
CPCC12Q1/6883C12Q2600/158C12Q2600/178C12Q2600/118
Inventor 袁平孟祥瑞吴文汇宫素岗孙媛媛刘锦铭王岚
Owner SHANGHAI PULMONARY HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap